Published in Ann Surg on July 01, 2000
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol (2014) 6.09
Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res (2006) 1.81
Survival of lymph node-negative breast cancer patients in relation to number of lymph nodes examined. Ann Surg (2003) 0.95
FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.86
(18)F-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer. Nucl Med Mol Imaging (2010) 0.85
Sentinel Lymph Node Biopsy for Breast Cancer: Our Technique and Future Directions in Lymph Node Staging. J Nucl Med Radiat Ther (2012) 0.83
A contemporary view of axillary dissection. Ann Surg (2000) 0.82
The evolution of the locoregional therapy of breast cancer. Oncologist (2011) 0.81
The number of tumor-free axillary lymph nodes removed as a prognostic parameter for node-negative breast cancer. Chin J Cancer (2014) 0.78
Value of sentinel lymph node biopsy in breast cancer patients with previous excisional biopsy. J Breast Cancer (2012) 0.75
What is the future of axillary surgery for breast cancer? Ecancermedicalscience (2013) 0.75
Failure of routine axillary nodal sampling to predict survival outcomes in lymph node-negative (N0) breast cancer. Ann Surg (2003) 0.75
Is Completion Axillary Dissection Necessary for This Patient? J Breast Health (2013) (2014) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg (1994) 8.85
Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53
Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet (1997) 6.99
Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med (1993) 3.54
Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med (1985) 3.41
Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg (1998) 2.90
Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst (1995) 2.52
Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg (1998) 2.32
Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer (1977) 2.16
Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg (1998) 2.02
Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst (1994) 1.77
Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. J Am Coll Surg (1996) 1.77
Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys (1993) 1.74
Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst (1992) 1.70
A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues. J Histochem Cytochem (1988) 1.67
Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer (1994) 1.58
Tumor size and axillary metastasis, a correlative occurrence in 1244 cases of breast cancer between 1980 and 1995. Eur J Surg Oncol (1997) 1.52
Axillary surgery in breast cancer--there still is a debate. Eur J Cancer (1993) 1.47
Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol (1993) 1.26
Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis. Cancer (1994) 1.14
Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol (1997) 1.01
Prognosis based on primary breast carcinoma instead of pathological nodal status. Br J Cancer (1994) 0.93
Omission of axillary lymph node dissection in early-stage breast cancer: effect on treatment outcome. Radiology (1995) 0.89
Axillary dissection can be avoided in selected breast cancer patients: analysis of 401 cases. Anticancer Res (1997) 0.87
Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability. J Am Coll Surg (1995) 0.86
Breast conservation therapy without axillary dissection. A rational treatment strategy in selected patients. Arch Surg (1993) 0.85
Simple mastectomy for early breast cancer and the behaviour of the untreated axillary nodes. Bull Cancer (1977) 0.85
Clinical behavior of untreated axillary nodes after local treatment for primary breast cancer. Ann Surg Oncol (1996) 0.84
Axillary dissection: when and how radical? Semin Surg Oncol (1997) 0.83
Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer. Arch Surg (1998) 0.82
Routine or delayed axillary dissection for primary breast cancer? Eur J Cancer (1995) 0.80
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med (1977) 3.45
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer (1982) 2.71
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet (1991) 2.58
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57
Stage I melanoma of the limbs: assessment of prognosis by levels of invasion and maximum thickness. Tumori (1978) 2.46
The FHIT gene 3p14.2 is abnormal in lung cancer. Cell (1996) 2.36
Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest (1996) 2.31
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer (1995) 2.28
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med (1988) 2.15
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol (2002) 2.14
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol (1999) 2.11
Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res (1998) 1.96
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol (1997) 1.84
Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst (1997) 1.79
Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 1.65
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci (2002) 1.65
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol (1998) 1.64
Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol (2008) 1.62
Results of adjuvant interferon study in WHO melanoma programme. Lancet (1994) 1.62
Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst (1997) 1.60
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest (1993) 1.57
Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol (1997) 1.55
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat (1999) 1.54
Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene (2012) 1.53
Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg (1991) 1.52
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene (1992) 1.51
Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg (1983) 1.50
Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res (1992) 1.50
Prevention and treatment of central venous catheter sepsis by exchange via a guidewire. A prospective controlled trial. Ann Surg (1983) 1.48
Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen. Eur J Cancer (1994) 1.47
Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. Istituto Nazionale per lo Studio e las Cura dei Tumori. Ann Oncol (2000) 1.46
The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg (2000) 1.43
Effect of imatinib on haematopoietic recovery following idarubicin exposure. Leukemia (2003) 1.43
Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer (1996) 1.43
HER2 as a prognostic factor in breast cancer. Oncology (2001) 1.43
Potentials of cell kinetics in the management of patients with ovarian cancers. Eur J Cancer (1992) 1.39
Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res (1997) 1.39
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37
Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer (2001) 1.36
Viral particles in cervical condylomatous lesions. Tumori (1978) 1.36
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res (1995) 1.34
Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res (1995) 1.33
Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer (1981) 1.33
A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene (2000) 1.33
N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res (1993) 1.33
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol (2009) 1.31
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol (2008) 1.31
Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol (2009) 1.30
Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest (2000) 1.30
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol (2006) 1.29
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol (2007) 1.29
Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res (1997) 1.29
HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol (2001) 1.28
Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci (2004) 1.28
Mucinous carcinoma of the breast. A clinicopathologic, histochemical, and immunocytochemical study with special reference to neuroendocrine differentiation. Am J Surg Pathol (1994) 1.28
Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg (1985) 1.27
Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest (2001) 1.26
Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. Proc Natl Acad Sci U S A (2004) 1.24
FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res (1999) 1.24
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol (2011) 1.24
Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst (1993) 1.23
Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer (2001) 1.22
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res (1994) 1.22
Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol (1988) 1.21
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol (2013) 1.20
Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res (1997) 1.18
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene (2006) 1.17
Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. Virology (2012) 1.16